Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis

• Market Cap: HK$142.00M
• Dividend Yield: N/A
• Average Volume (3M): 553.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: -4.57%
• EPS Growth: 52.37%
• Country: HK
• Employees: 311
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.25
• Shares Outstanding: 200,000,000
• 10 Day Avg. Volume: 893,680
• 30 Day Avg. Volume: 553,600
• PEG Ratio: -0.09
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -30.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: HK$0.50 ▼(-29.58%Downside)

Mediwelcome Healthcare Management & Technology Inc. faces significant financial challenges, impacting its overall score. Positive technical indicators provide some support, but valuation issues due to negative earnings and a lack of dividend yield limit its appeal. Continued financial and operational improvements are crucial.

Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model

Company Description

Mediwelcome Healthcare Management & Technology Inc. (2159) is a company operating within the healthcare sector, primarily focusing on providing comprehensive healthcare management services and technological solutions. The company specializes in offering medical conference services, continuing medical education, and hospital management consulting. By leveraging advanced technology, Mediwelcome aims to enhance healthcare delivery and management efficiency.

How the Company Makes Money

Mediwelcome Healthcare Management & Technology Inc. generates revenue through multiple streams within the healthcare industry. The primary revenue sources include organizing medical conferences and events, which attract healthcare professionals and industry stakeholders, generating income through participation fees and sponsorships. Additionally, the company offers continuing medical education programs, providing valuable training and development for healthcare professionals, thus earning revenue through course fees and partnerships with educational institutions. Mediwelcome also provides hospital management consulting services, assisting healthcare facilities in optimizing their operations and improving patient care, charging fees for their consulting expertise. Strategic partnerships with hospitals, pharmaceutical companies, and educational entities further bolster their revenue streams, allowing the company to expand its service offerings and market reach.

Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview

Summary

Mediwelcome Healthcare Management & Technology Inc. faces financial challenges with declining revenues and persistent losses. The company's negative cash flows and decreasing equity present significant risks, although there is some cost management improvement and moderate leverage.

Income Statement

The company's revenue has been declining, with a significant drop from 2021 to 2024. The EBIT and net income margins are negative, indicating operational challenges and losses. However, there is a slight improvement in gross profit margin from 2023 to 2024, suggesting some cost management progress.

Balance Sheet

The company has maintained positive stockholders' equity, though it has declined over recent years. The debt-to-equity ratio remains moderate, showing some leverage but not excessively risky. The equity ratio is decreasing, indicating lower asset financing through equity, which could pose a risk if liabilities increase.

Cash Flow

The company struggles with cash flow, with negative operating and free cash flows in recent years. The operating cash flow to net income ratio is not meaningful due to negative values, presenting challenges in cash generation. Although there was a significant capital expenditure reduction, it wasn't enough to offset cash flow deficits.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	321.56M	331.31M	323.37M	708.36M	432.29M
Gross Profit	51.00M	29.89M	32.55M	93.60M	96.31M
EBITDA	-33.61M	-74.53M	-69.08M	17.72M	41.06M
Net Income	-45.24M	-94.10M	-93.74M	4.64M	21.04M
Balance Sheet
Total Assets	194.09M	214.32M	317.83M	366.70M	280.08M
Cash, Cash Equivalents and Short-Term Investments	71.66M	80.35M	154.02M	174.83M	104.89M
Total Debt	47.73M	31.13M	26.48M	25.18M	25.43M
Total Liabilities	120.81M	94.35M	116.97M	73.21M	109.08M
Stockholders Equity	71.14M	116.13M	195.02M	283.11M	161.18M
Cash Flow
Free Cash Flow	-27.10M	-77.18M	-22.75M	-24.73M	17.31M
Operating Cash Flow	-14.05M	-75.58M	-18.46M	262.00K	31.12M
Investing Cash Flow	-326.00K	16.46M	-8.36M	-16.77M	-10.98M
Financing Cash Flow	5.68M	906.00K	54.00K	92.84M	-4.79M

Mediwelcome Healthcare Management & Technology Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Neutral. The current price of 0.71 is above the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.56, and above the 200-day MA of 0.47, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 43.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2159.

Mediwelcome Healthcare Management & Technology Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2138	66 Neutral	HK$628.16M	19.67	-8.91%	1.75%	169.20%	―
Sector *	57 Neutral	£4.68B	8.52	-61.44%	496.52%	33.02%	4.62%
2159	55 Neutral	HK$142.00M	―	-48.20%	―	-4.57%	52.37%
9686	49 Neutral	HK$757.69M	―		―	―	―
9686	49 Neutral	HK$757.69M	―		―	―	―
0401	46 Neutral	HK$41.46M	―	-9.43%	―	-3.12%	-2869.57%
2158	45 Neutral	HK$5.06B	―	-2.97%	―	11.00%	56.87%
2251	44 Neutral	HK$1.36B	―	-18.19%	―	-24.50%	-93.44%
2251	44 Neutral	HK$1.36B	―	-18.19%	―	-24.50%	-93.44%

Mediwelcome Healthcare Management & Technology Inc. Corporate Events

Mediwelcome Completes HK$16 Million Share Placement

Mediwelcome Healthcare Management & Technology Inc. has successfully completed the placement of 40 million new shares, raising approximately HK$16 million in gross proceeds. The funds will be used for general working capital, and the placement has slightly altered the company’s shareholding structure without any placee becoming a substantial shareholder.

Mediwelcome Clarifies RSU Scheme Status in 2024 Annual Report

Mediwelcome Healthcare Management & Technology Inc. has issued a supplemental announcement regarding its 2024 Annual Report, specifically addressing the status of its RSU Scheme. The company clarified that no RSUs were granted or agreed to be granted during 2024, and the number of unvested RSUs for employees remained at zero throughout the year. This announcement does not affect other information in the 2024 Annual Report, indicating stability in the company’s reporting and operations.

Mediwelcome Healthcare Successfully Passes AGM Resolutions

Mediwelcome Healthcare Management & Technology Inc. announced the successful passing of all proposed resolutions at its Annual General Meeting held on June 25, 2025. The resolutions included the re-election of directors, re-appointment of auditors, and granting of mandates for share issuance and repurchase, all of which were unanimously approved by shareholders, indicating strong support for the company’s strategic direction.

Mediwelcome Announces Share Placement to Raise HK$16 Million

Mediwelcome Healthcare Management & Technology Inc. has announced a placement of new shares under a general mandate, involving up to 40 million shares at a price of HK$0.40 per share. This move is expected to raise approximately HK$16 million in gross proceeds, with net proceeds of around HK$15.45 million intended for general working capital. The placement represents a significant portion of the company’s shares and is offered at a discount to recent trading prices, indicating a strategic effort to bolster financial resources.

Mediwelcome Announces Capital Reduction in Subsidiary

Mediwelcome Healthcare Management & Technology Inc. announced a capital reduction for one of its subsidiaries, the Target Company, which will see Beijing Medi Healthcare, a group entity, reduce its registered capital by approximately RMB3.1 million, equating to 51% of the Target Company’s existing capital. This move will result in Beijing Medi Healthcare ceasing to hold any interest in the Target Company, leading to the exclusion of the Target Company’s financial results from Mediwelcome’s consolidated financial statements. The capital reduction is deemed a discloseable transaction under Hong Kong’s listing rules, and the consideration for the reduction was set at RMB7.0 million, based on an independent valuation reflecting market conditions.

Mediwelcome Announces Annual General Meeting with Key Resolutions

Mediwelcome Healthcare Management & Technology Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Beijing. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of the company’s auditor, and the approval of a general mandate for the directors to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities, potentially impacting its market position and shareholder value.

Mediwelcome Enhances Governance with New Nomination Committee

Mediwelcome Healthcare Management & Technology Inc. has established a Nomination Committee to enhance its corporate governance structure. The committee, primarily composed of independent non-executive directors, is tasked with reviewing the board’s composition and recommending qualified candidates for directorships. This move is expected to strengthen the company’s strategic alignment and ensure diversity and expertise within its leadership.